Evidence map›Paper›PMID 30827681›Full record

ArticleCell2019

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.

Peter van Galen, Volker Hovestadt, Marc H Wadsworth Ii, Travis K Hughes, Gabriel K Griffin, Sofia Battaglia, Julia A Verga, Jason Stephansky, Timothy J Pastika, Jennifer Lombardi Story and 9 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 749 papers.

0numbers the graph read from it
0cells of the map it votes in
749citing papers in PubMed
59.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

749 citing papers in PubMed, 1,153 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Spatial Transcriptomics Analysis of Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  5. Review
  6. Cancers · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Machine learning-driven M2 macrophage signature for precision prediction of survival and therapy response in acute myeloid leukemia.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  12. iScience · 2026
    Article
  13. Article
  14. Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

689 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Peter van GalenDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Volker HovestadtDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Marc H Wadsworth IiBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Institute for Medical Engineering & Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Travis K HughesBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Institute for Medical Engineering & Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Gabriel K GriffinDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Sofia BattagliaDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Julia A VergaDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Jason StephanskyLudwig Center at Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Timothy J PastikaLudwig Center at Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jennifer Lombardi StoryCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Geraldine S PinkusDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Olga PozdnyakovaDepartment of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Ilene GalinskyDana-Farber Cancer Institute, Boston, MA 02215, USA.
Richard M StoneDana-Farber Cancer Institute, Boston, MA 02215, USA.
Timothy A GraubertCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Alex K ShalekBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Institute for Medical Engineering & Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Jon C AsterLudwig Center at Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Andrew A LaneLudwig Center at Harvard Medical School, Boston, MA 02115, USA; Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bradley E BernsteinDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Ludwig Center at Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: bernstein.bradley@mgh.harvard.edu.
Center for Cancer Research · USDana-Farber Cancer Institute · USHarvard University · USMassachusetts Institute of Technology · USBrigham and Women's Hospital · USBroad Institute · USMassachusetts General Hospital · US

Funding

Center for Cell CircuitsRM1HG006193 · NHGRI · BROAD INSTITUTE, INC. · PI BLAINEY, PAUL CLARK, HACOHEN, NIR · 2016 to 2020
$14.9M
Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI GRAUBERT, TIMOTHY A · 2017 to 2021
$10.6M
Epigenetic plasticity in tumor initiation and evolutionDP1CA216873 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BERNSTEIN, BRADLEY EVAN · 2016 to 2020
$5.9M
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)R37CA225191 · NCI · DANA-FARBER CANCER INST · PI LANE, ANDREW A · 2018 to 2024
$3.0M
Single-molecule systems for decoding combinatorial chromatin modificationsR01HG009269 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI BERNSTEIN, BRADLEY EVAN · 2016 to 2019
$2.7M
NCI NIH HHS DP1 CA216873NHGRI NIH HHS R01 HG009269
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease that resides within a complex microenvironment, complicating efforts to understand how different cell types contribute to disease progression. We combined single-cell RNA sequencing and genotyping to profile 38,410 cells from 40 bone marrow aspirates, including 16 AML patients and five healthy donors. We then applied a machine learning classifier to distinguish a spectrum of malignant cell types whose abundances varied between patients and between subclones in the same tumor. Cell type compositions correlated with prototypic genetic lesions, including an association of FLT3-ITD with abundant progenitor-like cells. Primitive AML cells exhibited dysregulated transcriptional programs with co-expression of stemness and myeloid priming genes and had prognostic significance. Differentiated monocyte-like AML cells expressed diverse immunomodulatory genes and suppressed T cell activity in vitro. In conclusion, we provide single-cell technologies and an atlas of AML cell states, regulators, and markers with implications for precision medicine and immune therapies. VIDEO ABSTRACT.

Indexed as

AdultBase SequenceBone MarrowBone Marrow CellsCell Line, TumorDisease ProgressionExome SequencingFemaleGenotypeHumansLeukemia, Myeloid, AcuteMachine LearningMaleMiddle AgedMutationPrognosisRNAacute myeloid leukemiacancer geneticsgenotypingimmunityleukemia stem cellssingle-cell RNA-sequencing

Identifiers

PMID30827681
PMCPMC6515904
OpenAlexW2916458303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.